

**Pubblicazioni**  
**Struttura Semplice Piattaforma di Biologia Integrata**

**2016-2019**

- 1) Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj E, Sulsenti R, Vergani E, Filipazzi P, De Laurentiis A, Lalli L, Di Guardo L, Patuzzo R, Vergani B, Casiraghi E, Cossa M, Gualeni A, Bollati V, Arienti F, De Braud F, Mariani L, Villa A, Altevogt P, Umansky V, Rodolfo M, Rivoltini L. Tumor derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. *J Clin Invest.* 2018;128:5505-5516.
- 2) Dugo M, Huang X, Iorio MV, Cataldo A, Tagliabue E, Daidone MG, Wu J, Orlandi R. MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. *Breast.* 2018;39:46-52.
- 3) Andriani F, Majorini MT, Mano M, Landoni E, Miceli R, Facchinetto F, Mensah M, Fontanella E, Dugo M, Giacca M, Pastorino U, Sozzi G, Delia D, Roz L, Lecis D. MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1 dependent manner. *J Hematol Oncol.* 2018;11:45.
- 4) Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, De Cecco L, Rizzetti MG, Zanframundo A, Aiello A, Carcangiu ML, Gloghini A, Ferrero S, Licitra L, Greco A, Fugazzola L, Locati LD, Borrello MG. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. *Endocr Relat Cancer.* 2018;25:217-231.
- 5) De Vecchi A, De Cecco L, Dugo M, Penso D, Dagradà G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. *Cancer Commun (Lond).* 2018;38:70.
- 6) Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. *Br J Cancer.* 2018;119:1487-1494.
- 7) Resteghini C, Trama A, Borgonovi E, Hosni H, Corrao G, Orlandi E, Calareso G, De Cecco L, Piazza C, Mainardi L, Licitra L. Big Data in Head and Neck Cancer, *Curr Treat Options Oncol.* 2018;19:62.
- 8) Andriani F, Landoni E, Mensah M, Facchinetto F, Miceli R, Tagliabue E, Giussani M, Callari M, De Cecco L, Colombo MP, Roz L, Pastorino U, Sozzi G. Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. *BMC Cancer.* 2018;18:899.
- 9) Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C, Pepe G, Lopez G, Monardo F, Bianchi A, D'Amore ESG, Gianelli U, Facchetti F, Berti E, Bhagat G. Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. *Mod Pathol.* 2018.
- 10) Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. *Oral Oncol.* 2018;82:144-151.
- 11) Peraldo-Neia C, Ostano P, Cavalloni G, Pignochino Y, Sangiolo D, De Cecco L, Marchesi E, Ribero D, Scarpa A, De Rose AM, Giuliani A, Calise F, Raggi C, Invernizzi P, Aglietta M, Chiorino G, Leone F. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. *BMC Genomics.* 2018;19(1):440.
- 12) Majorini MT, Manenti G, Mano M, De Cecco L, Conti A, Pincioli P, Fontanella E, Tagliabue E, Chiodoni C, Colombo MP, Delia D, Lecis D. cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. *Cell Death Differ.* 2018;25:2147-2164.
- 13) Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement PM, Coropciuc R, Hauben E, Licitra LF. Activity and safety of afatinib in a

- window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). *Ann Oncol.* 2018;12:985-991.
- 14) Verri C, Borzi C, Holscher T, Dugo M, Devecchi A, Drake K, Sestini S, Suatoni P, Romeo E, Sozzi G, Pastorino U, Boeri M. Mutational profile from targeted NGS predicts survival in LDCT screening-detected lung cancers. *J Thorac Oncol.* 2017;12:922-931
  - 15) Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. *J Invest Dermatol.* 2017;137:484-493.
  - 16) Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. *Oncogene.* 2017;36:1721-1732.
  - 17) Sensi M, Canevari S, Tomassetti A. Axl in ovarian cancer: a step forward for clinical breakthrough? *Oncotarget.* 2016;7:80105-80106.
  - 18) Vallacchi V, Camisaschi C, Dugo M, Vergani E, Deho P, Gualeni A, Huber V, Gloghini A, Maurichi A, Santinami M, Sensi M, Castelli C, Rivoltini L, Rodolfo M. microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. *Genes (Basel).* 2016;7:pii:E124.
  - 19) Dugo M, Cotroneo CE, Lavoie-Charland E, Incarbone M, Santambrogio L, Rosso L, van den Berge M, Nickle D, Paré PD, Bossé Y, Dragani TA, Colombo F. Human Lung Tissue Transcriptome: Influence of Sex and Age. *PLoS One.* 2016;11:e0167460.
  - 20) Gimondi S, Dugo M, Vendramin A, Bermema A, Biancon G, Cavané A, Corradini P, Carniti C. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. *Exp Hematol.* 2016;44:624-634.e1.
  - 21) Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, Sangaletti S, Di Carlo E, Tripodo C, Colombo MP. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. *Oncotarget.* 2016;7:3905-20.
  - 22) Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. *Oncotarget.* 2016;7:4428-41.
  - 23) Bossi P, Bergamini C, Siano M, Cossu Rocca M, Spongolini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. *Clin Cancer Res.* 2016;22:3961-70.
  - 24) Disciglio V, Devecchi A, Palumbo O, Carella M, Penso D, Milione M, Valle G, Pierotti MA, Vitellaro M, Bertario L, Canevari S, Signoroni S, De Cecco L. Whole exome sequencing and single nucleotide polymorphism array analyses to identify germline alterations in genes associated with testosterone metabolism in a patient with androgen insensitivity syndrome and early-onset colorectal cancer. *Chin J Cancer.* 2016;35:51.
  - 25) Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. *Lancet Oncol.* 2016;17:1137-46.